You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IDH2 Gene Mutation

Showing 1 - 25 of 9,174
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

Recruiting
  • Low-grade Glioma
  • +4 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 19, 2022

Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Edmonton, Alberta, Canada
  • +1 more
Jan 31, 2023

IDH Mutation, IDH1 Mutation, IDH2 Gene Mutation Trial in Chicago (Ivosidenib, Enasidenib, Fedratinib)

Recruiting
  • IDH Mutation
  • +4 more
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia Trial in Baltimore,

Active, not recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Baltimore, Maryland
  • +2 more
Feb 25, 2022

Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to

Withdrawn
  • Blasts Under 5 Percent of Peripheral Blood White Cells
  • +4 more
  • Buffalo, New York
  • +1 more
Mar 8, 2021

Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

Recruiting
  • Recurrent IDH1/2 Mutated Glioma
  • Paris, France
    Pitie Salpetriere Hospital
Aug 29, 2022

Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

Not yet recruiting
  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma Metastatic
  • (no location specified)
Oct 10, 2023

Her-2 Negative Breast Cancer, HRR Gene Mutation Trial in Guangzhou (Camrelizumab, Fluzoparib, Nab-paclitaxel)

Recruiting
  • Her-2 Negative Breast Cancer
  • HRR Gene Mutation
  • Guangzhou, Guangdong, China
    First Affiliated Hospital, Sun Yat-Sen University
Mar 7, 2023

An Intervention to Increase Genetic Testing in Families Who May

Recruiting
  • BRCA1 Mutation
  • +21 more
  • Intervention Arm At-risk Relative/ARR Contacts
  • +5 more
  • Basking Ridge, New Jersey
  • +7 more
Nov 22, 2022

Glioma Trial in United States (AG881)

Active, not recruiting
  • Glioma
  • Los Angeles, California
  • +8 more
May 16, 2022

Leukemia, Leukemia, Myeloid, Monocytic Leukemia Trial in Palo Alto (Enasidenib mesylat dose escalation)

Recruiting
  • Leukemia
  • +2 more
  • Enasidenib mesylat dose escalation
  • Palo Alto, California
    Stanford Cancer Institute
May 12, 2022

AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor Trial (REC-4881)

Not yet recruiting
  • AXIN1 Gene Mutation
  • +2 more
  • (no location specified)
Aug 21, 2023

ARID1A Gene Mutation, ATM Gene Mutation, ATR Gene Mutation Trial in United States (Olaparib)

Recruiting
  • ARID1A Gene Mutation
  • +15 more
  • Scottsdale, Arizona
  • +4 more
Dec 13, 2022

Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States

Recruiting
  • Accelerated/Blast-phase Myeloproliferative Neoplasm
  • +2 more
  • Scottsdale, Arizona
  • +10 more
May 9, 2022

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation Trial in Sacramento (Niraparib, Niraparib Tosylate Monohydrate,

Recruiting
  • ATM Gene Mutation
  • +16 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 27, 2022

Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation Trial in San Francisco (Niraparib, Irinotecan)

Not yet recruiting
  • Metastatic Solid Tumor
  • +4 more
  • San Francisco, California
    University of California, San Francisco
Jan 12, 2023

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation Trial in Baltimore (Recommendation for treatment with

Recruiting
  • Metastatic Solid Tumor
  • +4 more
  • Recommendation for treatment with immunotherapy
  • Baltimore, Maryland
    Johns Hopkins University
Sep 8, 2022

Isocitrate Dehydrogenase Gene Mutation Trial in Spain, United States (HMPL-306)

Recruiting
  • Isocitrate Dehydrogenase Gene Mutation
  • Santa Monica, California
  • +8 more
Feb 22, 2022

Leber Hereditary Optic Neuropathy (LHON) Trial (NFS-02 Injection)

Not yet recruiting
  • Leber Hereditary Optic Neuropathy (LHON)
  • NFS-02 Injection
  • (no location specified)
Apr 6, 2023

Leber Congenital Amaurosis Trial in Shanghai (HG004)

Recruiting
  • Leber Congenital Amaurosis
  • HG004
  • Shanghai, Shanghai, China
    Xinhua Hospital affiliated with Shanghai Jiao Tong UniversitySch
Oct 12, 2023

Trial

Not yet recruiting
  • Leber Hereditary Optic Neuropathy (LHON)
  • NR082 Injection
  • Injection needle
  • (no location specified)
Jan 30, 2023

Patients With G2019S LRRK2 Parkinson's Disease

Suspended
  • Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene
  • Observational
  • Culver City, California
    Science 37
Aug 15, 2022